
CTRV
Other · Other · $5.9M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2019
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2018 | Time not confirmed | -0.37 | -0.63 | -70.3% |
| Aug 14, 2018 | Time not confirmed | -0.39 | -0.38 | +2.6% |
| Apr 3, 2018 | Time not confirmed | -0.56 | -0.16 | +71.4% |
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside…